A Modified Electrochemical Sensor Based on N,S-Doped Carbon Dots/Carbon Nanotube-Poly(Amidoamine) Dendrimer Hybrids for Imatinib Mesylate Determination [PDF]
Biosensors, 2023 Imatinib mesylate, an anticancer drug, is prescribed to treat gastrointestinal stromal tumors and chronic myelogenous leukemia. A hybrid nanocomposite of N,S-doped carbon dots/carbon nanotube-poly(amidoamine) dendrimer (N,S-CDs/CNTD) was successfully ...
Maryam Saleh Mohammadnia +3 more
doaj +3 more sources
Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects [PDF]
Clinical and Translational Science, 2022 For the long‐term efficacy of dry eye disease treatment, relieving underlying inflammation is necessary. Imatinib mesylate is a novel ophthalmic formulation of imatinib mesylate, which is expected to alleviate inflammation by inhibiting the discoidin ...
Joo Young Na +7 more
doaj +2 more sources
Green biosynthesis of magnetic iron oxide nanoparticles using Mentha longifolia for imatinib mesylate delivery [PDF]
IET Nanobiotechnology, 2022 In this work, the rapid, facile, and eco‐friendly green process was introduced in the preparation of β‐cyclodextrin/magnetic iron oxide nanoparticles by using the aqueous Mentha longifolia extracts of Mentha longifolia.
Bahareh Naeimipour +4 more
doaj +2 more sources
Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity [PDF]
International Journal of Nanomedicine, 2015 Gregory Marslin,1 Ann Mary Revina,2,3 Vinoth Kumar Megraj Khandelwal,4 Krishnamoorthy Balakumar,5 Jose Prakash,6 Gregory Franklin,1,* Caroline J Sheeba2,3,7,*1AgroBioPlant Group, Centre for the Research and Technology of Agro-Environment and Biological ...
Marslin G +6 more
doaj +4 more sources
Pathological complete response in advanced gastric stromal tumor after imatinib mesylate therapy: a case report [PDF]
Journal of Medical Case Reports, 2011 Introduction Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit. Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors.
Maazaz Khalid +11 more
doaj +4 more sources
Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1 [PDF]
Clinical Case Reports, 2020 Imatinib mesylate seemed to inhibit development of cutaneous neurofibromas (c‐NFs) and promote growth of pre‐existing c‐NFs in our neurofibromatosis type 1 case. This report potentially provides new findings in the effects of imatinib mesylate.
Ken‐ichi Yasuda +4 more
doaj +2 more sources
Malignant stromal tumor of the stomach with giant cystic liver metastases prior to treatment with imatinib mesylate [PDF]
Vojnosanitetski Pregled, 2013 Introduction. Gastrointestinal stromal tumors (GISTs) are rare and account for 0.1%-3% of all gastrointestinal neoplasms. GISTs are most commonly located in the stomach (60%) and 20%-25% are malignant, with metastases involving the peritoneum or
Čolović Radoje +5 more
doaj +3 more sources
Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate [PDF]
Pharmaceutics, 2019 The proposed study examined the characterization and stability of solid-state amorphous imatinib mesylate (IM) after 15 months under controlled relative humidity (60 ± 5%) and temperature (25 ± 2 °C) conditions. After 2 weeks, and 1, 3, 6,
Bożena Karolewicz +3 more
doaj +2 more sources
Imatinib-induced interstitial pneumonitis – a literature review and case report [PDF]
, 2020 Imatinib is generally well tolerated, with mild common side effects such as nausea and vomiting, diarrhea, muscle cramps, fatigue, skin rash and edema; however, pulmonary complications are uncommon. A 73-year-old woman undergoing one month treatment with
Ciulei, George +12 more
core +2 more sources
Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor [PDF]
Yeungnam University Journal of Medicine, 2019 Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare.
Min Kyu Kang +2 more
doaj +1 more source